Cardiol Therapeutics Inc(CRDL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:38 PM ET (Korea 9/12 08:38)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.25 | Insider Own | 3.01% | Shs Outstand | 115.9M | Perf Week | -7.64% |
| Market Cap | 0.23B | Forward P/E | - | EPS next Y | 34.66% | Insider Trans | - | Shs Float | 113.3M | Perf Month | 31.25% |
| Enterprise Value | 0.21B | PEG | - | EPS next Q | -0.05 | Inst Own | 26.02% | Short Float | 2.58% | Perf Quarter | 86.45% |
| Income | -0.02B | P/S | - | EPS this Y | -6.66% | Inst Trans | 1.5% | Short Ratio | 2.75 | Perf Half Y | 90% |
| Sales | 0.00B | P/B | 13.65 | EPS next 5Y | 79.41% | ROA | -139.86% | Short Interest | 2.93M | Perf YTD | 109.16% |
| Book/sh | 0.15 | P/C | 12.68 | EPS past 3/5Y | 9.88% 11.6% | ROE | -192.95% | 52W High | -14.74% ($2.34) | Perf Year | 86.45% |
| Cash/sh | 0.16 | P/FCF | - | Sales past 3/5Y | - | ROIC | -145.37% | 52W Low | 126.7% ($0.88) | Perf 3Y | 113.37% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 28.85% | Gross Margin | - | Volatility(W/M) | 6.64% 8.61% | Perf 5Y | -50.86% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.15 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.55 | EPS Q/Q | 47.67% | Profit Margin | - | RSI (14) | 55.72 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.55 | Sales Q/Q | - | SMA20 | -1.08% ($2.02) | Beta | 0.86 | Target Price | $8.5 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/13 | SMA50 | 28.93% ($1.55) | Rel Volume | 1.17 | Prev Close | $1.98 |
| Employees | 23 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 48.49% - | SMA200 | 62.36% ($1.23) | Avg Volume(3M) | 1.06M | Price | $2 |
| IPO | 2019/1/15 | Option/Short | Yes/Yes | Trades | 2000 | Volume | 1,242,963 | Change | 0.76% |
Company
CRDL is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🫀 Cardiol Therapeutics is a clinical-stage life sciences company developing anti-inflammatory therapeutics that target inflammation and fibrosis in heart disease. Its lead candidate, CardiolRx, is being advanced in recurrent pericarditis, myocarditis, and heart failure, and is based on a mechanism that modulates the inflammasome pathway to address cardiovascular diseases with significant unmet need.
Over the past 1 year, on the higher side
15% below its 1-year high.
CRDL has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -6.7% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by +113.4% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 26.0%.
Tap to view numbers
It ranks #4 in the industry
Based on market cap of $233M.
CRDL $233M PER -
TAK $58B PER -
TEVA $43B PER 62.4
HLN $40B PER 18.9
FAQ
What kind of company is CRDL?
CRDL belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of CRDL?
The market cap of CRDL is approximately $233M, ranking 3,986 within its sector.
What is the 52-week high and low for CRDL?
CRDL has recorded a 52-week high of $2.34 and a low of $0.88.
